Cancer Cell Article Demonstrates First Definitive Evidence for Targeting of Pol I as New Approach to Cancer Therapy

San Diego, July 10, 2012 – Cylene Pharmaceuticals today announced that research collaborators at the Peter MacCallum Cancer Centre (Peter Mac) in Melbourne, Australia have established, for the first time, that RNA Polymerase I (Pol I) activity is essential for cancer cell survival and that its inhibition selectively activates p53 to kill tumors.  Published today in Cancer Cell, the findings show that Cylene’s Pol I inhibitor, CX-5461, selectively destroys cancer by activating p53 in malignant but not in normal cells.

More from
Client News